Reneo Pharmaceuticals Price on August 12, 2024
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
If you're considering investing in Reneo Stock, it is important to understand the factors that can impact its price. As of today, the current price of Reneo Pharmaceuticals stands at 18.20, as last reported on the 4th of December, with the highest price reaching 19.00 and the lowest price hitting 16.80 during the day. Reneo Pharmaceuticals is somewhat reliable given 3 months investment horizon. Reneo Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.28, which implies the firm had a 0.28% return per unit of risk over the last 3 months. We have analyze and collected data for thirty different technical indicators, which can help you to evaluate if expected returns of 1.13% are justified by taking the suggested risk. Use Reneo Pharmaceuticals Risk Adjusted Performance of 0.0861, semi deviation of 2.63, and Coefficient Of Variation of 973.22 to evaluate company specific risk that cannot be diversified away.
Reneo Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
Reneo |
Sharpe Ratio = 0.2801
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RPHM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.04 actual daily | 35 65% of assets are more volatile |
Expected Return
| 1.13 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 22 78% of assets perform better |
Based on monthly moving average Reneo Pharmaceuticals is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reneo Pharmaceuticals by adding it to a well-diversified portfolio.
Related Headline
Royalty Pharma Headline on 12th of August 2024
Disposition of 2182 shares by Urist Marshall of Royalty Phar... by Urist Marshall
Filed transaction by Royalty Pharma Plc Officer: Evp, Research & Investments. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Reneo Pharmaceuticals Valuation on August 12, 2024
It is possible to determine the worth of Reneo Pharmaceuticals on a given historical date. On August 12, 2024 Reneo was worth 13.4 at the beginning of the trading date compared to the closed value of 13.4. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Reneo Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Reneo Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Reneo Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Reneo Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 13.50 | 13.60 | 13.35 | 13.50 | 5,977 | |
08/12/2024 | 13.40 | 13.50 | 13.10 | 13.40 | 6,124 |
| 13.10 | 14.10 | 13.10 | 13.80 | 26,795 |
| Backtest Reneo Pharmaceuticals | | | Reneo Pharmaceuticals History | | | Reneo Pharmaceuticals Valuation | Previous | Next |
Reneo Pharmaceuticals Trading Date Momentum on August 12, 2024
| On August 13 2024 Reneo Pharmaceuticals was traded for 13.80 at the closing time. The top price for the day was 14.10 and the lowest listed price was 13.10 . The trading volume for the day was 26.8 K. The trading history from August 13, 2024 was a factor to the next trading day price boost. The trading delta at closing time against the next closing price was 2.99% . The trading delta at closing time against the current closing price is 14.18% . |
Reneo Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Reneo Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Reneo Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Reneo financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Reneo Pharmaceuticals Stock history
Reneo Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Reneo is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Reneo Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Reneo Pharmaceuticals stock prices may prove useful in developing a viable investing in Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in Irvine, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.
Reneo Pharmaceuticals Stock Technical Analysis
Reneo Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
Price Boundaries
Reneo Pharmaceuticals Period Price Range
Low | December 4, 2024
| High |
0.00 | 0.00 |
Reneo Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Reneo Pharmaceuticals December 4, 2024 Market Strength
Market strength indicators help investors to evaluate how Reneo Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Reneo Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Reneo Pharmaceuticals stock market strength indicators, traders can identify Reneo Pharmaceuticals entry and exit signals to maximize returns
Reneo Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Reneo Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Reneo Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Reneo to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0861 | |||
| Jensen Alpha | 0.2659 | |||
| Total Risk Alpha | (0.12) | |||
| Sortino Ratio | 0.067 | |||
| Treynor Ratio | 0.5632 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |